This scheme aims to drive fundamental discoveries stemming from MRC’s research boards and the wider academic community along the developmental pathway towards patient benefit and or commercialisation.
The Developmental Pathway Funding Scheme (DPFS) is the core MRC translational research scheme and forms a key part of our clinical and translational research strategy.
The aim of the scheme is to drive fundamental discoveries stemming from our research boards and the wider academic community along the developmental pathway towards patient benefit and or commercialisation.
All disease areas are eligible for support from the scheme and applications made through this scheme can focus on the development of any innovative solution that aims to improve the prevention, diagnosis, prognosis or treatment of significant health needs. We also support projects that focus on developing research tools or platform technologies that increase the efficiency of developing interventions.
Individual projects can start and finish at any point along the translational pathway from initial development, through pre-clinical and clinical refinement to early phase clinical trials (up to and including phase IIa).
MRC encourages partnerships in applications, with charities or industry, where these add value to the project.
If your application involves the collaboration of one or more industrial partners, you should review the information published within the MRC industry collaboration framework (ICF) to decide if you should submit your application under the ICF.
After reading the ICF information, if you decide that your application will include industry collaboration, you will need to include the following within your application for each collaborating industry partner:
Please note that we do not fund the work of your industrial partners.